Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Pharmacoepidemiology and Drug Safety|November 13, 2002
Changes in prescribed drug doses after market introductionEibert R Heerdink, John Urquhart, Hubert G Leufkens
Pharmacoepidemiology and Drug Safety|March 6, 2003
Comparing patterns of long-term benzodiazepine use between a Dutch and a Swedish communityRolf van Hulten, Dag Isacson, Albert Bakker, et al.
Pharmacy World & Science : PWS|May 3, 2005
Initial benzodiazepine use and improved health-related quality of lifeRolf van Hulten, Bart Teeuw, Albert Bakker, et al.
Drug Discovery Today|October 18, 2011
Effective pharmaceutical regulation needs alignment with doctorsHans C Ebbers, Toine Pieters, Hubert G Leufkens, et al.
European Journal of Clinical Pharmacology|March 1, 2003
Initial 3-month usage characteristics predict long-term use of benzodiazepines: an 8-year follow-upRolf van Hulten, K Bart Teeuw, Albert Bakker, et al.
Plos Medicine|December 10, 2009
A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an exampleTjeerd-Pieter van Staa, Hubert G Leufkens, Bill Zhang, et al.
Biologicals : Journal of the International Association of Biological Standardization|January 17, 2021
Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case studyAli M Alsamil, Thijs J Giezen, Toine C Egberts, et al.
Pharmaceuticals (Basel, Switzerland)|March 6, 2021
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab BiosimilarsAli M Alsamil, Thijs J Giezen, Toine C Egberts, et al.
Journal of Public Health Policy|March 10, 2017
Health system productivity change in Zambia: A focus on the child health servicesTom Achoki, Yohannes Kinfu, Felix Masiye, et al.
Pageof 4